An open-label, healthy subject, two-part study to assess the effect of verapamil on systemic exposure of EP395 (Part A), and to assess the effect of EP395 on systemic exposure of midazolam and digoxin (Part B)

2023-506345-34-00 Protocol EP395-004 Human pharmacology (Phase I) - Other Ended

Start 23 Oct 2023 · End 2 Jan 2024 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol EP395-004

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 1
Sites 1

Chronic obstructive pulmonary disease (COPD)

Key facts

Sponsor
Epiendo Pharmaceuticals ehf., Epiendo Pharmaceuticals ehf.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Respiratory Tract Diseases [C08]
Trial duration
23 Oct 2023 → 2 Jan 2024
Decision date (initial)
2023-09-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic obstructive pulmonary disease (COPD)

VersionLevelCodeTermSystem organ class
21.1 PT 10009033 Chronic obstructive pulmonary disease 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Epiendo Pharmaceuticals ehf.

Sponsor organisation
Epiendo Pharmaceuticals ehf.
Address
Bjargargata 1
City
Reykjavík
Postcode
102
Country
Iceland

Scientific contact point

Organisation
Epiendo Pharmaceuticals ehf.
Contact name
Kate Hanrott

Public contact point

Organisation
Epiendo Pharmaceuticals ehf.
Contact name
Kate Hanrott

Epiendo Pharmaceuticals ehf.

Sponsor organisation
Epiendo Pharmaceuticals ehf.
Address
Bjargargata 1
City
Reykjavík
Postcode
102
Country
Iceland

Scientific contact point

Organisation
Epiendo Pharmaceuticals ehf.
Contact name
Kate Hanrott

Public contact point

Organisation
Epiendo Pharmaceuticals ehf.
Contact name
Kate Hanrott

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ended 36 1
Rest of world 0

Investigational sites

Sweden

1 site · Ended
CTC Clinical Trial Consultants AB
CTC Oscar, Dag Hammarskjolds Vag 10b, Uppsala Domkyrkofors., Uppsala

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2023-10-23 2024-01-02 2023-10-23 2024-01-02

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-07-06 Sweden Acceptable
2023-09-25
2023-09-26